Company intelligence / Profile preview

Surface Logix

Massachusetts, United Statessurfacelogix.net ↗

Ownership: Private
Development stage: Commercial

Overview

Surface Logix developed several novel small molecule drug candidates using its proprietary Pharmacomer technology. Lead assets included SLx‑2101 (a long‑acting PDE5 inhibitor in Phase II for cardiovascular indications), SLx‑4090 (an oral MTP inhibitor in Phase IIb for dyslipidemia/diabetes), and SLx‑2119 (a selective ROCK2 inhibitor with potential applications across metabolic syndrome, diabetes, cancer, autoimmune diseases). The company demonstrated rapid progression from discovery to clinic but was acquired by Nano Terra around 2011. Some assets were subsequently licensed out or further developed by other companies.

Therapeutic areas: Metabolic DisordersCardiovascularEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Kadmon Pharmaceuticals

Beyond the preview

Go deeper on Surface Logix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surface Logix.

Explore the full profile